Aerosol fluoroquinolone formulations for improved pharmacokinetics
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/397
A61K-031/535
A61P-011/06
A61K-031/47
A61K-047/02
A61K-031/4375
A61K-031/538
A61K-009/00
출원번호
US-0574680
(2009-10-06)
등록번호
US-8815838
(2014-08-26)
발명자
/ 주소
Griffith, David C.
Dudley, Michael N.
Surber, Mark W.
Bostian, Keith A.
Rodny, Olga
출원인 / 주소
Griffith, David C.
인용정보
피인용 횟수 :
9인용 특허 :
149
초록▼
The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infection
The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.
대표청구항▼
1. A method for treating a pulmonary infection, comprising administering to a human having said pulmonary infection an aerosol of a solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation to achieve a maximum lung sputum concentration (Cmax) of at least 1200 mg/L and a lung
1. A method for treating a pulmonary infection, comprising administering to a human having said pulmonary infection an aerosol of a solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation to achieve a maximum lung sputum concentration (Cmax) of at least 1200 mg/L and a lung sputum area under the curve (AUC) of at least 1500 h·mg/L, wherein the solution comprises a divalent or trivalent cation concentration from about 50 mM to about 400 mM, and a levofloxacin or ofloxacin concentration from between about 50 mg/ml to about 200 mg/ml. 2. The method of claim 1, wherein the solution consists essentially of levofloxacin or ofloxacin and the divalent or trivalent cation. 3. The method of claim 1, wherein the solution comprises no lactose. 4. The method of claim 1, comprising achieving a maximum lung sputum concentration (Cmax) of at least 1700 mg/L. 5. The method of claim 1, comprising achieving a maximum lung sputum concentration (Cmax) of at least 2000 mg/L. 6. The method of claim 1, comprising achieving a maximum lung sputum concentration (Cmax) of at least 3000 mg/L. 7. The method of claim 1, comprising achieving a maximum lung sputum concentration (Cmax) of at least 4000 mg/L. 8. The method of claim 1, comprising achieving a lung sputum area under the curve (AUC) of at least 1700 h·mg/L. 9. The method of claim 1, comprising achieving a lung sputum area under the curve (AUC) of at least 2000 h·mg/L. 10. The method of claim 1, comprising achieving a lung sputum area under the curve (AUC) of at least 3000 h·mg/L. 11. The method of claim 1, comprising achieving a lung sputum area under the curve (AUC) of at least 4000 h·mg/L. 12. The method of claim 1, wherein the solution comprises a divalent or trivalent cation concentration from about 100 mM to about 300 mM, and a levofloxacin or ofloxacin concentration from about 75 mg/ml to about 150 mg/ml. 13. The method of claim 1, wherein the solution comprises a divalent or trivalent cation concentration from about 150 mM to about 250 mM, and a levofloxacin or ofloxacin concentration from about 90 mg/ml to about 125 mg/ml. 14. The method of claim 1, wherein the solution comprises an osmolality from about 300 mOsmol/kg to about 600 mOsmol/kg, and a pH from about 5 to about 8. 15. The method of claim 1, wherein the solution comprises an osmolality from about 350 mOsmol/kg to about 425 mOsmol/kg, and a pH from about 5 to about 6.5. 16. The method of claim 1, wherein the solution comprises a pH from about 5.5 to about 6.5. 17. The method of claim 1, wherein the divalent or trivalent cation is selected from magnesium, calcium, zinc, copper, aluminum, and iron. 18. The method of claim 1, wherein the solution comprises magnesium chloride. 19. The method of claim 1, wherein the solution comprises a levofloxacin or ofloxacin concentration from about 90 mg/ml to about 110 mg/ml, a magnesium chloride concentration from about 175 mM to about 225 mM, a pH from about 5 to about 7; an osmolarity from about 300 mOsmol/kg to about 500 mOsmol/kg, and lacks lactose. 20. The method of claim 1, wherein the human has a pulmonary disorder selected from the group consisting of cystic fibrosis, chronic obstructive pulmonary disease, chronic bronchitis, bronchiectasis, and asthma. 21. The method of claim 1, wherein the pulmonary infection comprises one or more bacteria selected from the group consisting of Pseudomonas aeruginosa, Pseudomonas fluorescens, Pseudomonas acidovorans, Pseudomonas alcaligenes, Pseudomonas putida, Stenotrophomonas maltophilia, Aeromonas hydrophilia, Escherichia coli, Citrobacter freundii, Salmonella typhimurium, Salmonella typhi, Salmonella paratyphi, Salmonella enteritidis, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Enterobacter cloacae, Enterobacter aerogenes, Klebsiella pneumoniae, Klebsiella oxytoca, Serratia marcescens, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Providencia alcalifaciens, Providencia rettgeri, Providencia stuartii, Acinetobacter calcoaceticus, Acinetobacter haemolyticus, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Yersinia intermedia, Bordetella pertussis, Bordetella parapertussis, Bordetella bronchiseptica, Haemophilus influenzae, Haemophilus parainfluenzae, Haemophilus haemolyticus, Haemophilus parahaemolyticus, Haemophilus ducreyi, Pasteurella multocida, Pasteurella haemolytica, Helicobacter pylori, Campylobacter fetus, Campylobacter jejuni, Campylobacter coli, Borrelia burgdorferi, Vibrio cholera, Vibrio parahaemolyticus, Legionella pneumophila, Listeria monocytogenes, Neisseria gonorrhoeae, Neisseria meningitidis, Burkholderia cepacia, Francisella tularensis, Kingella, and Moraxella. 22. The method of claim 1, wherein the pulmonary infection is caused by a gram-negative anaerobic bacteria. 23. The method of claim 1, wherein the pulmonary infection is caused by one or more of the bacteria selected from the group consisting of Bacteroides fragilis, Bacteroides distasonis, Bacteroides 3452A homology group, Bacteroides vulgatus, Bacteroides ovalus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides eggerthii, and Bacteroides splanchnicus. 24. The method of claim 1, wherein the pulmonary infection is caused by a gram-positive bacteria. 25. The method of claim 1, wherein the pulmonary infection is caused by one or more of the bacteria selected from the group consisting of Corynebacterium diphtherias, Corynebacterium ulcerans, Streptococcus pneumoniae, Streptococcus agalactiae, Streptococcus pyogenes, Streptococcus milleri; Streptococcus (Group G); Streptococcus (Group C/F); Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus intermedius, Staphylococcus hyicus subsp. hyicus, Staphylococcus haemolyticus, Staphylococcus hominis, and Staphylococcus saccharolyticus. 26. The method of claim 1, wherein the pulmonary infection is caused by a gram-positive anaerobic bacteria. 27. The method of claim 1, wherein the pulmonary infection is caused by one or more bacteria selected from the group consisting of Clostridium difficile, Clostridium perfringens, Clostridium tetini, and Clostridium botulinum. 28. The method of claim 1, wherein the pulmonary infection is caused by an acid-fast bacteria. 29. The method of claim 1, wherein the pulmonary infection is caused by one or more bacteria selected from the group consisting of Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium intracellulare, and Mycobacterium leprae. 30. The method of claim 1, wherein the pulmonary infection is caused by an atypical bacteria. 31. The method of claim 1, wherein the pulmonary infection is caused by one or more bacteria selected from the group consisting of Chlamydia pneumoniae and Mycoplasma pneumoniae. 32. The method of claim 1, wherein the aerosol comprises a mass median aerodynamic diameter from about 2 microns to about 5 microns with a geometric standard deviation less than or equal to about 2.5 microns. 33. The method of claim 1, wherein the aerosol comprises a mass median aerodynamic diameter from about 2.5 microns to about 4.5 microns with a geometric standard deviation less than or equal to about 1.8 microns. 34. The method of claim 1, wherein the aerosol comprises a mass median aerodynamic diameter from about 2.8 microns to about 4.3 microns with a geometric standard deviation less than or equal to about 2 microns. 35. The method of claim 1, comprising producing the aerosol with a vibrating mesh nebulizer. 36. The method of claim 35, wherein the vibrating mesh nebulizer is a PARI E-FLOW® nebulizer. 37. The method of claim 1, wherein a respirable drug dose (RDD) of at least about 20 mg of levofloxacin or ofloxacin is administered to the lung. 38. The method of claim 1, wherein a respirable drug dose (RDD) of at least about 100 mg of levofloxacin or ofloxacin is administered to the lung. 39. The method of claim 1, wherein a respirable drug dose (RDD) of at least about 125 mg of levofloxacin or ofloxacin is administered to the lung. 40. The method of claim 1, wherein a respirable drug dose (RDD) of at least about 150 mg of levofloxacin or ofloxacin is administered to the lung. 41. The method of claim 1, wherein a loaded dose of at least about 100 mg is aerosolized. 42. The method of claim 1, wherein a loaded dose of at least about 200 mg is aerosolized. 43. The method of claim 1, wherein a loaded dose of at least about 300 mg is aerosolized. 44. The method of claim 1, wherein the aerosol is administered to the lung in less than about 10 minutes. 45. The method of claim 1, wherein the aerosol is administered to the lung in less than about 5 minutes. 46. The method of claim 1, wherein the aerosol is administered to the lung in less than about 3 minutes. 47. The method of claim 1, wherein the aerosol is administered to the lung in less than about 2 minutes. 48. The method of claim 1, further comprising co-administering an additional active agent selected from the group consisting of antibiotics, bronchodilators, anticholinergics, glucocorticoids, eicosanoid inhibitors, CFTR modulators, agents to restore airway surface liquid, anti-inflammatory agents, and combinations thereof. 49. The method of claim 48, wherein co-administering comprises inhaling the additional active agent. 50. The method of claim 48, wherein the antibiotic is selected from the group consisting of tobramycin, aztreonam, ciprofloxacin, azithromycin, tetracycline, quinupristin, linezolid, vancomycin, and chloramphenicol, colisitin and combinations thereof. 51. The method of claim 48, wherein the bronchodilator is selected from the group consisting of salbutamol, levosalbuterol, terbutaline, fenoterol, terbutlaine, pirbuterol, procaterol, bitolterol, rimiterol, carbuterol, tulobuterol, reproterol, salmeterol, formoterol, arformoterol, bambuterol, clenbuterol, indacterol, theophylline, roflumilast, cilomilast, and combinations thereof. 52. The method of claim 48, wherein the anticholinergic is selected from the group consisting of ipratropium, tiotropium, and combinations thereof. 53. The method of claim 48, wherein the glucocorticoid is selected from the group consisting of prednisone, fluticasone, budesonide, mometasone, ciclesonide, beclomethasone, and combinations thereof. 54. The method of claim 48, wherein the CFTR modulator is selected from the group consisting of VX-770, atluren, VX-809, and combinations thereof. 55. The method of claim 48, wherein the agents to restore airway surface liquid is selected from the group consisting of denufosol, mannitol, GS-9411, SPI-8811, and combinations thereof. 56. The method of claim 48, wherein the anti-inflammatory agent is selected from the group consisting of ibuprofen, sildenafil, simavastatin, and combinations thereof. 57. The method of claim 48, wherein the eicosanoid inhibitor is selected from the group consisting of montelukast, pranlukast, zafirlukast, zileuton, ramatroban, seratrodast, and combinations thereof. 58. The method of claim 1, comprising administering the aerosol once daily. 59. The method of claim 1, comprising administering the aerosol twice daily. 60. A method of treating a chronic lung infection, comprising administering to a subject having a chronic lung infection an aerosol of a solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation to achieve a maximum lung sputum concentration (Cmax) of at least 1200 mg/L and a lung sputum area under the curve (AUC) of at least 1500 h·mg/L, wherein the solution comprises a divalent or trivalent cation concentration from about 50 mM to about 400 mM, and a levofloxacin or ofloxacin concentration from between about 50 mg/ml to about 200 mg/ml. 61. The method of claim 60, wherein the solution consists essentially of levofloxacin or ofloxacin and the divalent or trivalent cation. 62. The method of claim 60, wherein the solution comprises no lactose. 63. The method of claim 60, wherein the human has a pulmonary disorder selected from the group consisting of cystic fibrosis, chronic obstructive pulmonary disease, chronic bronchitis, bronchiectasis, pneumonia, and asthma. 64. The method of claim 60, wherein the solution comprises a divalent or trivalent cation concentration from about 100 mM to about 300 mM, and a levofloxacin or ofloxacin concentration from about 75 mg/ml to about 150 mg/ml. 65. The method of claim 60, wherein the solution comprises a divalent or trivalent cation concentration from about 150 mM to about 250 mM, and a levofloxacin or ofloxacin concentration from about 90 mg/ml to about 125 mg/ml. 66. The method of claim 60, wherein the solution comprises an osmolality from about 300 mOsmol/kg to about 600 mOsmol/kg, and a pH from about 5 to about 8. 67. The method of claim 60, wherein the solution comprises an osmolality from about 350 mOsmol/kg to about 425 mOsmol/kg, and a pH from about 5 to about 6.5. 68. The method of claim 60, wherein the solution comprises a pH from about 5.5 to about 6.5. 69. The method of claim 60, wherein the divalent or trivalent cation is selected from magnesium, calcium, zinc, copper, aluminum, and iron. 70. The method of claim 60, wherein the solution comprises magnesium chloride. 71. The method of claim 60, further comprising co-administering an additional active agent selected from the group consisting of antibiotics, bronchodilators, anticholinergics, glucocorticoids, eicosanoid inhibitors, and combinations thereof. 72. The method of claim 71, wherein co-administering comprises inhaling the additional active agent. 73. The method of claim 71, wherein the antibiotic is selected from the group consisting of tobramycin, aztreonam, ciprofloxacin, azithromycin, tetracycline, quinupristin, linezolid, vancomycin, and chloramphenicol, colisitin and combinations thereof. 74. The method of claim 71, wherein the bronchodilator is selected from the group consisting of salbutamol, levosalbuterol, terbutaline, fenoterol, terbutlaine, pirbuterol, procaterol, bitolterol, rimiterol, carbuterol, tulobuterol, reproterol, salmeterol, formoterol, arformoterol, bambuterol, clenbuterol, indacterol, theophylline, roflumilast, cilomilast, and combinations thereof. 75. The method of claim 71, wherein the anticholinergic is selected from the group consisting of ipratropium, tiotropium, and combinations thereof. 76. The method of claim 71, wherein the glucocorticoid is selected from the group consisting of prednisone, fluticasone, budesonide, mometasone, ciclesonide, beclomethasone, and combinations thereof. 77. The method of claim 71, wherein the eicosanoid inhibitor is selected from the group consisting of montelukast, pranlukast, zafirlukast, zileuton, ramatroban, seratrodast, and combinations thereof. 78. The method of claim 60, comprising administering the aerosol once daily. 79. The method of claim 60, comprising administering the aerosol twice daily. 80. The method of claim 1, wherein the solution comprises a levofloxacin or ofloxacin concentration from about 90 mg/ml to about 110 mg/ml, a magnesium chloride concentration from about 175 mM to about 225 mM, a pH from about 5 to about 7; an osmolarity from about 300 mOsmol/kg to about 500 mOsmol/kg, and lacks lactose.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (149)
Schmidt, James N.; Engelbreth, Daniel; Blacker, Rick, Aerosol delivery apparatus with positive expiratory pressure capacity.
James N. Schmidt CA; Jerry Grychowski ; Daniel K. Engelbreth CA; Robert Morton CA; Martin P. Foley CA, Aerosol medication delivery apparatus and system.
Osbakken, Robert S.; Hale, Mary Anne; Leivo, Frederick T.; Munk, James D., Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis.
Gordeev, Mikhail F.; Patel, Dinesh V.; Barbachyn, Michael R.; Gage, James R., Antimicrobial quinolone derivatives and use of the same to treat bacterial infections.
Gordeev, Mikhail F.; Patel, Dinesh V.; Barbachyn, Michael R.; Gage, James R., Antimicrobial quinolone derivatives and use of the same to treat bacterial infections.
Hodson Peter D. (Trowell GB3) Baum Eric A. (Loughborough GB3) Smith David K. (Loughborough GB3) Kuepper Anton (Kaarst DEX) Wilby Matthew J. (Loughborough GB3), Breath actuated inhaler having an electromechanical priming mechanism.
Newell Robert E. (Pinner GB2) Rand Paul K. (Nitchin GB2) Fitzsimmons Robert A. (Barnard Castle GB2), Devices for administering medicaments to patients.
Casper, Robert A.; Leith, Frank A.; Gardner, David L.; Snow, John M.; Lyon, Zachary W.; Farrar, David S., Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament.
Mulhauser Paul (New York NY) Karg Jeffrey (Waldwick NY) Foxen Thomas (Brooklyn NY) Brooks Christopher J. (Glen Head NY), Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same.
Domagala John M. (Canton MI) Kiely John S. (Ann Arbor MI) Schroeder Mel C. (Dexter MI), Individual stereosiomers of 7-[3-(aminoalkyl)-1-pyrrolidinyl]-quinolones and naphthyridones as antibacterial agents.
Burns James S. (Darien CT) Marshak Daniel R. (Cold Spring Harbor NY), Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means.
Ambrosio Thomas J. ; Ashley Charles R. ; Bilanin Alan J. ; Huck Charles M. ; Kaufman Andrew E. ; Kenyon David J. ; Manthena Srinivas ; Sochon Henry R. ; Wilkinson Ken ; Yang Tsong-Toh, Inhaler for powdered medications.
Hess Joseph,CHX ; Bo Hu,CHX ; Weber Raphael,CHX ; Ortega Isabel,CHX ; Barraud Cedric,CHX ; van der Schoot Bart,CHX ; de Rooij Nicolaas Frans,CHX ; de Heij Bas,CHX, Liquid droplet spray device for an inhaler suitable for respiratory therapies.
Zoltan Bart J. (Old Tappan NJ) Laube Beth L. (Baltimore MD) Adams ; III George K. (Baltimore MD) Bow Clark F. (Newton NJ) Devito Ralph J. (Stanhope NJ) Harrington Walter (Flanders NJ) Hoffman Louis S, Medication delivery system phase two.
Smith Adrian E. ; Burr John D. ; Etter Jeffery W. ; Axford George S. ; Lyons Shirley W. ; Platz Robert M., Method and apparatus for dispersion of dry powder medicaments.
Blineau Joseph (Rennes FRX) Pommier Daniel (Mordelles FRX) Thomas Claude (Chasne sur Illet FRX), Multiplex channels for continuous flow for numerical signal.
Nowacki Christopher (Arlington Heights IL) Brisson Alfred G. (Kildeer IL) Dela-Cruz Exequiel (Arlington Heights IL), Pediatric asthmatic medication inhaler.
Arnold Klaus (Ingelheim am Rhein DEX) Grass Peter (Ingelheim am Rhein DEX) Knecht Adolf (Freiburg DEX) Roos Robert (Ingelheim am Rhein DEX) Sluke Gerhard (Ingelheim am Rhein DEX) Thieme Herbet (Ingel, Powders for inhalation.
Knight Jack V. (Houston TX) Wilson ; Jr. Samuel Z. (Houston TX), Small particle aerosol generator for treatment of respiratory disease including the lungs.
Welsh, Michael J.; Zabner, Joseph, Use of xylitol to reduce ionic strength and activate endogenous antimicrobials for prevention and treatment of infections.
Griffith, David C.; Dudley, Michael N.; Surber, Mark W.; Bostian, Keith A.; Rodny, Olga, Aerosol fluoroquinolone formulations for improved pharmacokinetics.
Griffith, David C.; Dudley, Michael N.; Surber, Mark W.; Bostian, Keith A.; Rodny, Olga, Aerosol fluoroquinolone formulations for improved pharmacokinetics.
Griffith, David C.; Dudley, Michael N.; Surber, Mark W.; Bostian, Keith A.; Rodny, Olga, Aerosol fluoroquinolone formulations for improved pharmacokinetics.
Karp, Gary Mitchell; Hwang, Seongwoo; Chen, Guangming; Almstead, Neil Gregory; Moon, Young-Choon, Compositions of 1,2,4-oxadiazole benzoic acid compounds and methods for their use.
Karp, Gary Mitchell; Hwang, Seongwoo; Chen, Guangming; Almstead, Neil Gregory; Moon, Young-Choon, Compositions of 1,2,4-oxadiazole benzoic acid compounds and methods for their use.
Loutit, Jeffery S.; Morgan, Elizabeth E.; Dudley, Michael N.; Griffith, David C.; Lomovskaya, Olga, Use of aerosolized levofloxacin for treating cystic fibrosis.
Loutit, Jeffery S.; Morgan, Elizabeth E.; Dudley, Michael N.; Griffith, David C.; Lomovskaya, Olga, Use of aerosolized levofloxacin for treating cystic fibrosis.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.